A real-world evidence study presented at the European Congress on Obesity Day 1 — Wilding et al., with a cohort of 89,718 patients initiating GLP-1 therapy — quantifies for the first time at this scale the relationship between achieved weight loss and reduction in obesity-related comorbidity risk. The findings simultaneously validate the “more weight loss equals more health benefits” narrative the field has assumed and surface a real-world adherence challenge that has been hiding behind the trial-population numbers.

The headline finding: among patients achieving ≥15% reduction in BMI on GLP-1 therapy, the risk of osteoarthritis was 37% lower, chronic kidney disease 30% lower, obstructive sleep apnea 69% lower, and heart failure 32% lower, compared to patients with less than 5% BMI reduction. All comparisons statistically significant.

The less-discussed finding: 50.1% of patients discontinued GLP-1 treatment within one year, defined as a treatment gap of 60 days or more.

The Cohort and the Method

The Wilding RWE study aggregated electronic health record data from 89,718 patients who initiated GLP-1 therapy. The cohort composition reflects the real-world prescribing pattern of the past 18 months:

• 75.6% on semaglutide (Ozempic, Wegovy, or oral formulations)
• 17.5% on tirzepatide (Mounjaro, Zepbound)
• 6.9% on liraglutide (Saxenda, Victoza)

Mean baseline characteristics: age 57.5 years, BMI 34.7, 61% with type 2 diabetes, 39% without. The age and comorbidity profile of the cohort closely mirrors the typical real-world GLP-1 prescribing population — older than the Phase 3 trials, with more comorbidities.

The analysis followed patients for at least 12 months and measured weight loss outcomes (categorized into bands), discontinuation rates (defined as 60-day treatment gaps), and incident comorbidity events.

The Weight-Loss Distribution

Patient outcomes were not uniform. The weight-loss distribution after one year:

| Weight-loss band | Proportion | |—|—| | <5% BMI reduction | 27.0% | | 5–<10% BMI reduction | 22.4% | | 10–<15% BMI reduction | 14.1% | | ≥15% BMI reduction | 15.8% | | BMI increase | 20.8% |

Roughly one in five patients (20.8%) had a BMI increase rather than a decrease, primarily attributable to early discontinuation. A quarter of patients achieved less than 5% BMI reduction — the threshold below which clinical guidelines typically do not consider weight-loss therapy successful. Only one in six (15.8%) achieved the ≥15% threshold associated with the largest comorbidity reductions.

The real-world weight-loss distribution is meaningfully different from the Phase 3 trial outcomes. STEP trials reported approximately 15–17% mean weight loss; SURMOUNT trials reported approximately 22%. The trial populations were highly selected for adherence and motivation, with intensive trial-protocol support. Real-world patients, in the absence of that support, show substantial heterogeneity.

The Comorbidity Dose-Response

For the patients who did achieve ≥15% BMI reduction, the comorbidity benefit was substantial. Risk reductions versus the <5% BMI reduction cohort:

• Osteoarthritis: 37% lower risk
• Chronic kidney disease: 30% lower risk
• Obstructive sleep apnea: 69% lower risk
• Heart failure: 32% lower risk

All statistically significant. The OSA finding is particularly striking — 69% risk reduction is comparable to surgical intervention rates for obesity-related sleep apnea. The osteoarthritis and heart failure findings align with the TRIUMPH-4 mechanism story (weight loss directly improves joint loading and cardiovascular function).

The dose-response framing matters editorially. The class is increasingly understood not as “GLP-1s reduce comorbidity risk” but as “weight loss reduces comorbidity risk, and GLP-1s are an effective mechanism for achieving weight loss.” The drug effect is mediated by the weight loss itself. Patients who achieve substantial weight loss capture substantial comorbidity benefit; patients who do not, do not.

The 50% Discontinuation Problem

The most clinically important finding in the study may be the simplest: half of patients discontinue GLP-1 therapy within one year. The definition (60+ day treatment gap) is conservative — some of those patients may resume therapy after the gap. But persistent adherence over the long term remains a substantial real-world problem.

Discontinuation reasons in the RWE data set included gastrointestinal intolerability, cost, lack of perceived progress, insurance changes, supply chain issues during the 2024–2025 shortage period, and uncategorized “other.” Without intervention support comparable to clinical trial protocols, real-world adherence falls well below the 80%+ adherence rates achieved in pivotal trials.

The 50% one-year discontinuation rate has substantial implications for the cost-effectiveness modeling that drives insurance coverage decisions. If half of patients discontinue, the long-term benefit estimates that assume sustained therapy overstate real-world outcomes. The Wilding et al. data is the first large-scale real-world quantification of this gap.

What This Means

For prescribers: the data supports continued GLP-1 prescribing with realistic expectations about adherence. Strategies that improve adherence — patient education, side-effect management protocols, regular follow-up, cost navigation — meaningfully affect long-term outcomes. The half of patients who discontinue within a year are not “GLP-1 failures” in a clinical sense; they are evidence that the class needs better real-world support structures.

For patients: GLP-1 therapy works substantially better when it is sustained. Patients planning to start GLP-1 therapy should plan for the realistic 6-to-12-month support needs — gastrointestinal management, cost navigation, schedule adherence — rather than treating it as a short-term intervention.

For the broader Peptidings audience: the dose-response between weight loss and comorbidity reduction is now quantified at a population scale. Patients achieving the highest weight-loss outcomes capture proportionally large comorbidity benefits — but most patients do not reach those weight-loss levels in real-world settings. The trial-versus-real-world gap is real.

References

1. Greater Weight Loss From GLP-1 Drugs Lowers Health Complication Risk. News-Medical. May 10, 2026. News-Medical
2. Benefits on Obesity-Linked Conditions of Losing More Weight With GLP-1 Treatment. EurekAlert. May 2026. EurekAlert
3. Benefits in Obesity-Linked Conditions of Losing More Weight. MedicalXpress. May 2026. MedicalXpress